Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Jul;48(8):2325-2328.
doi: 10.1007/s00259-020-05102-4.

177Lu-PSMA for advanced prostate cancer: are we ready to play big?

Charisma Hehakaya  1 , Ellen H M Moors  2 , Helena M Verkooijen  3 , Diederick E Grobbee  4 , Frederik A Verburg  5 , Marnix G E H Lam  3
Affiliations
Editorial

177Lu-PSMA for advanced prostate cancer: are we ready to play big?

Charisma Hehakaya et al. Eur J Nucl Med Mol Imaging. 2021 Jul.
No abstract available

PubMed Disclaimer

References

    1. Bashir MN. Epidemiology of prostate cancer. Asian Pac J Cancer Prev. 2015;16:5137–41. - DOI
    1. Brausi M, et al. ECCO essential requirements for quality cancer care: prostate cancer. Crit Rev Oncol Hematol. 2020;148:102861. - DOI
    1. Ladurner M, Horninger W, Bektic J. Lutetium-PSMA therapy—a new therapeutic option in metastatic castration-resistant prostate cancer? Memo - Mag Eur Med Oncol. 2018;11:301–4.
    1. Emmett L, et al. Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. J Med Radiat Sci. 2017;64:52–60. - DOI
    1. von Eyben FE, et al. Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. Eur J Nucl Med Mol Imaging. 2018;45:496–508. - DOI

Publication types

LinkOut - more resources